Stockscreener 앱 받기
1.16
4.50%
0.05
시장 영업 전:
1.15
-0.01
-0.86%
전일 마감가:
$1.11
열려 있는:
$1.16
하루 거래량:
128.91K
Relative Volume:
0.67
시가총액:
$63.16M
수익:
$42,000
순이익/손실:
$-11.44M
주가수익비율:
-4.6549
EPS:
-0.2492
순현금흐름:
$-7.93M
1주 성능:
+2.65%
1개월 성능:
-7.94%
6개월 성능:
-61.84%
1년 성능:
-49.34%
1일 변동 폭
$1.09
$1.16
1주일 범위
$1.07
$1.21
52주 변동 폭
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
명칭
Entera Bio Ltd
전화
972-2-532-7151
주소
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.16 | 63.16M | 42,000 | -11.44M | -7.93M | -0.2492 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-22 | 개시 | Aegis Capital | Buy |
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
Entera Bio (ENTX) upgraded to buy: Here's what you should know - MSN
Entera Bio (ENTX) to Release Earnings on Friday - MarketBeat
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know - sharewise.com
HC Wainwright Has Strong Estimate for Entera Bio Q1 Earnings - MarketBeat
What is HC Wainwright's Estimate for Entera Bio Q1 Earnings? - MarketBeat
HC Wainwright Has Lowered Expectations for Entera Bio (NASDAQ:ENTX) Stock Price - MarketBeat
H.C. Wainwright lowers Entera Bio stock price target on dilution By Investing.com - Investing.com South Africa
Entera Bio Price Target Cut to $9.00/Share From $10.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright lowers Entera Bio stock price target on dilution - Investing.com
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near - MarketBeat
Leading Osteoporosis Experts Are Lining Up Behind Entera Bio (NASDAQ: ENTX) - TradingView
Articles from Entera Bio Ltd. - FinancialContent
ENTX (Entera Bio Ltd. Ordinary Shares) rises 4.42 percent on Q4 2025 EPS beat despite sharp year over year revenue decline.Post Announcement - Xã Thanh Hà
ENTX (Entera Bio Ltd. Ordinary Shares) Q4 2025 narrower than expected loss pushes shares 6.67 percent higher in daily trading.Trending Volume Leaders - Xã Thanh Hà
ENTX (Entera Bio Ltd. Ordinary Shares) tops Q4 2025 EPS estimates, shares climb nearly seven percent on upbeat investor reaction.Real Trader Insights - Cổng thông tin điện tử tỉnh Lào Cai
ENTX: Oral anabolic EB613 could transform osteoporosis care by improving access and adherence - TradingView
ENTX: Oral anabolic EB613 could close major osteoporosis treatment gaps and improve patient outcomes - TradingView
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613Oral Anabolic Tablet Opportunity - Yahoo Finance
Entera Bio (ENTX) Stock: Institutional Signals (Technical Weakness) 2026-04-20Low Risk Entry - Cổng thông tin điện tử tỉnh Lào Cai
Entera Bio (ENTX) Stock: Worth Buying? (Investor Interest) 2026-04-18Fundamentals - Xã Châu Thành
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - marketscreener.com
Entera Bio to Host Key Opinion Leader Webinar Highlighting - GlobeNewswire
Should I Sell Entera Bio (ENTX) Stock Now | Price at $1.13, Down 1.74%Shared Trade Alerts - Newser
Bear Alert: Should I invest in Entera Bio Ltd before earnings2026 Highlights & AI Powered Market Entry Strategies - baoquankhu1.vn
Entera Bio raises $10M in private placement led by BVF Partners - Investing.com Australia
Greenberg Traurig Represents Entera Bio in $10M Private Placement - National Today
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners - Bitget
Market Leaders: Is Entera Bio Ltd stock risky to hold now2026 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Entera Bio Ltd. Announces Private Placement and Securities Purchase Agreement for Phase 3 Osteoporosis Study Funding - Minichart
ENTX Technical Analysis & Stock Price Forecast - Intellectia AI
Entera Bio Announces $10 Million Private Placement Financing - TipRanks
Entera Bio Raises $10 Million in Private Placement With BVF Partners, Adds Registration Rights - TradingView — Track All Markets
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
Fresh $10M gives Entera Bio runway for Phase 3 osteoporosis study - Stock Titan
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds - The Manila Times
Entera Bio Ltd. announced that it expects to receive $10 million in funding - marketscreener.com
Denali Therapeutics Receives $200 Million Following FDA Accelerated Approval of Tividenofusp Alfa and Royalty Agreement Closing - Minichart
Net current asset value per share of Entera Bio Ltd. – LS:A2JQXP - TradingView
Stock market today: S&P 500, Dow futures gain as Trump calls Iran's new leaders 'very reasonable'—Palantir, Rezolve AI, Entera Bio in focus - MSN
Entera Bio Ltd (ENTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):